← biote Corp. (BTMD) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
biote Corp. (BTMD)
Medicinal Chemicals & Botanical Products · market cap $76M · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
7
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Biote Corp. (BTMD) is a small-cap medicinal/botanical-sector company with a $98M market cap, 223 employees, and ~$2.33 share price. The company carries a diversified but largely mid-stage pipeline spanning oncology, autoimmune, and hematology indications, with its lead asset being the established TKI sunitinib in a Phase 3 trial for metastatic renal cell carcinoma. Financially, the company generates meaningful revenue (~$192M in 2025) but is severely leveraged, with only $5.3M cash against $102.5M net debt.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2027-09-15 (est.)Phase 2 · IMA402 (Phase Ia)imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| RY_SW01 cell injection | Phase 2 | Lupus Nephritis |
| Basic treatment | Phase 2 | Systemic Sclerosis |
| IMA402 (Phase Ia) | Phase 2 | Refractory Cancer |
| Endoxana, Leukine, IMA910 | Phase 2 | Colorectal Carcinoma |
| KL003 Cell Injection Drug Product | Phase 2 | Transfusion-dependent Beta-Thalassemia |
| donor-derived NK cell infusion | Phase 2 | Non-small Cell Lung Cancer |
| Endoxana, IMA901, Leukine | Phase 2 | Renal Cell Carcinoma |
Price & technical context
3-month
-46.5%
6-month
-18.9%
12-month
-61.3%
52-wk range
$1.16–$3.19
vs 50-day MA
-27.3%
vs 200-day MA
-41.5%
Realized vol
75.4%
Max drawdown
-83.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BTMD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.